lymphoma and multiple myeloma
Haematology · 2011–2012
3decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| plerixafor Treatment, in combination with granulocyte-colony stimulating factor (G-CSF), of lymphoma and multiple myeloma in patients requiring autologous stem cell… | Jul 2012 | Noted | no section in document |
| plerixafor use of plerixafor in mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation… | Nov 2011 | Not recommended | unclear |
| plerixafor Mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with lymphoma… | Nov 2011 | Not recommended | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.